Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

2014 Genitourinary Cancers Symposium

30 Jan - 1 Feb 2014
San Francisco Marriott Marquis, San Francisco, CA, United States of America
ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic bo...
Dr Sten Nilsson - Karolinska University Hospital, Stockholm, Sweden
ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic bone metastases ( Dr Sten Nilsson - Karolinska University Hospital, Stockholm, Sweden )
1 Feb 2014
Predictive power of PSA patterns during off-time treatment periods with intermit...
Dr Rafael Sanchez-Salas - Institut Mutualiste Montsouris, Paris, France
Predictive power of PSA patterns during off-time treatment periods with intermittent androgen deprivation ( Dr Rafael Sanchez-Salas - Institut Mutualiste Montsouris, Paris, France )
1 Feb 2014
Review of the latest abstracts from the COU-AA-302 trial
Dr Chris Parker and Prof Stephane Oudard
Review of the latest abstracts from the COU-AA-302 trial ( Dr Chris Parker and Prof Stephane Oudard )
31 Jan 2014
The use of abiraterone and enzalutamide against CRPC
Dr Chris Parker and Dr Kurt Miller
The use of abiraterone and enzalutamide against CRPC ( Dr Chris Parker and Dr Kurt Miller )
31 Jan 2014
Enzalutamide improves survival in men with metastatic castration-resistant prost...
Dr Tomasz M. Beer - Oregon Health & Science University, Portland, USA
Enzalutamide improves survival in men with metastatic castration-resistant prostate cancer ( Dr Tomasz M. Beer - Oregon Health & Science University, Portland, USA )
31 Jan 2014
Latest treatment for CRPC: Combinations, sequencing, radiotherapy and immunother...
Dr Maria De Santis - Kaiser Franz Josef Hospital, Vienna, Austria
Latest treatment for CRPC: Combinations, sequencing, radiotherapy and immunotherapy ( Dr Maria De Santis - Kaiser Franz Josef Hospital, Vienna, Austria )
31 Jan 2014
MET variant as a prognostic marker in clear cell renal cell carcinoma
Dr Ari Hakimi - Memorial Sloan-Kettering Cancer Center, New York, USA
MET variant as a prognostic marker in clear cell renal cell carcinoma ( Dr Ari Hakimi - Memorial Sloan-Kettering Cancer Center, New York, USA )
31 Jan 2014
Results of orteronel plus prednisone in the TAK-700 trial on mCRPC
Dr Robert Dreicer - Cleveland Clinic, Cleveland, USA
Results of orteronel plus prednisone in the TAK-700 trial on mCRPC ( Dr Robert Dreicer - Cleveland Clinic, Cleveland, USA )
31 Jan 2014
Gleason score efficacy predictions in abiraterone acetate therapy with mCRPC
Dr Karim Fizazi - Institut Gustave Roussy, Paris, France
Gleason score efficacy predictions in abiraterone acetate therapy with mCRPC ( Dr Karim Fizazi - Institut Gustave Roussy, Paris, France )
31 Jan 2014
Results of the MARS study in renal cell carcinoma
Dr Vincent Launay-Vacher - Pitie-Salpetriere Hospital, Paris, France
Results of the MARS study in renal cell carcinoma ( Dr Vincent Launay-Vacher - Pitie-Salpetriere Hospital, Paris, France )
31 Jan 2014
Advances in prostate cancer - a decade in review
Dr Karim Fizazi, Dr Cora Sternberg, Dr John Fitzpatrick, Dr Heather Payne, Dr Pe...
Advances in prostate cancer - a decade in review ( Dr Karim Fizazi, Dr Cora Sternberg, Dr John Fitzpatrick, Dr Heather Payne, Dr Peter Nelson )
30 Jan 2014
Dissecting the biology of the androgen receptor pathway
Dr Peter Nelson - Fred Hutchinson Cancer Research Center, Seattle, USA
Dissecting the biology of the androgen receptor pathway ( Dr Peter Nelson - Fred Hutchinson Cancer Research Center, Seattle, USA )
30 Jan 2014